Immune tolerance to hepatitis C virus acquired during engraftment of bone marrow transplant

Journal of Viral Hepatitis

Volumn 12, Issue 6, 2005, Pages 604-608

  Godkin, A ^a,b   Openshaw, P ^a   Thomas, H C ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

CD4+ T cell; Epitopes; HLA

Indexed keywords

HLA DR11 ANTIGEN; RECOMBINANT INTERFERON; VIRUS PROTEIN;

ACUTE DISEASE; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CASE REPORT; CELLULAR IMMUNITY; CONTROLLED STUDY; DONOR; FEMALE; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; LYMPHOCYTE COUNT; MALE; MEMORY CELL; PRIORITY JOURNAL; RECIPIENT; T LYMPHOCYTE ACTIVATION; THYMUS; VIREMIA; VIRUS VIRULENCE;

ADULT; BONE MARROW TRANSPLANTATION; CD4-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; IMMUNE TOLERANCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 27444439216     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2005.00627.x     Document Type: Article

References (19)

1. Douek D, Vescio R, Betts M et al. Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lancet 2000; 355: 1875-1881.
2. Lauer G, Walker B. Medical progress: hepatitis C infection. N Engl J Med 2001; 345(1): 41-52.
3. Kalams S, Walker B. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 1998; 188: 2199-2204.
4. Hill A. The immunogenetics of human infectious diseases. Annu Rev Immunol 1998; 16: 593-617.
5. Diepolder H, Zachoval R, Hoffmann R et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995; 346(8981): 1006-1007.
6. Takaki A, Wiese M, Maertens G et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000; 6(5): 578-582.
7. Godkin A, Jeanguenat N, Thursz M, Openshaw P, Thomas H. Characterisation of novel HLA-DR11-restricted HCV epitopes reveals both qualitative and quantitative differences in HCV-specific CD4+ T cell responses in chronically infected and non-viraemic patients. Eur J Immunol 2001; 31: 1438-1446.
8. Lechner F, Wong D, Dunbar R et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191(9): 1499-1512.
9. Godkin A, Smith K, Willis A et al. Naturally processed HLA class II peptides reveal highly conserved immunogenic flanking region sequence preferences that reflect antigen processing rather than peptide-MHC interactions. J Immunol 2001; 166: 6720-6727.
10. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708-712.
11. Godkin A, Thomas H, Openshaw P. Evolution of epitope-specific memory CD4+ T cells after clearance of hepatitis C virus. J Immunol 2002; 169: 2210-2214.
12. Kisielow P, Teh H, Bluthmann H, von Boehmer H. Positive selection of antigen-specific T cells in thymus by restricting MHC molecules. Nature 1988; 335(6192): 730-733.
13. Kisielow P, Bluthmann H, Staerz U, Steinmetz M, von Boehmer H. Tolerance in T-cell-receptor transgenic mice involves deletion of nonmature CD4+8+ thymocytes. Nature 1988; 333(6175): 742-746.
14. Goldrath A, Bevan M. Selecting and maintaining a diverse T-cell repertoire. Nature 1999; 402: 255-262.
15. Goodnow C. Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. Proc Natl Acad Sci USA 1996; 93: 2264-2271.
16. Pircher H, Rohrer U, Moskophidis D, Zinkernagel R, Hengartner H. Low receptor avidity required for thymic clonal deletion than for effector T-cell function. Nature 1991; 351: 482-485.
17. Neumann A, Lam N, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha treatment. Science 1998; 282: 103-107.
18. Zeitz M, Quinn T, Graeff A, Schwarting R, James S. Oral administration of cyclosporin does not prevent expansion of antigen-specific, gut-associated, and spleen lymphocye populations during Chlamydia trachomatis proctitis in non-human primates. Dig Dis Sci 1989; 34(4): 585-595.
19. Prud'homme G, Parfrey N, Vanier L. Cyclosporine-induced autoimmunity and immune hyperreactivity. Autoimmunity 1991; 9(4): 345-356.